Responses
Oral Presentations
Plenary symposium 12: combination therapy (with a special focus on local IO)
12.03 ISB 1442, a first-in-class CD38 and CD47 bispecific antibody innate cell modulator for the treatment of CD38 positive hematological malignancies
Compose a Response to This Article
Other responses
No responses have been published for this article.